-
Mashup Score: 2Novel CD4+ Donor Lymphocyte Therapy Shows Promising Remission Rates in High-Risk Myeloid Malignancie | Blood Cancers Today - 4 day(s) ago
CD4+ MMUDLI treatment achieved complete remission rates of more than 50% in treatment-refractory myelodysplastic syndrome.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Clonal Analysis Reveals Shared Splicing Neoantigens and Therapeutic Targets | Blood Cancers Today - 18 day(s) ago
Research shows that shared splicing neoantigens and key molecular pathways could inform future therapies for MDS and myelodysplasia-related AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🚨 New insights into #MDS and #AML: a clonal analysis reveals shared splicing neoantigens and therapeutic targets that could inform future therapies. 📰 Read about the study presented at #ASH24 by @nsalomonis of @CincyChildrens. ➡️ https://t.co/lNfh8IpAdh https://t.co/tsJOMx1efi
-
A novel first-in-human CD4+ mismatched unrelated donor lymphocyte infusion treatment achieved complete remission rates of >50% in treatment-refractory #MDS and secondary #AML The study was presented at #ASH24 by Hany Elmariah, MD, of @MoffittNews. ➡️ https://t.co/eru2WUUc02 https://t.co/e8LfQoLuMK